CPC C07K 16/06 (2013.01) [A61K 39/155 (2013.01); A61K 39/39516 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); C07K 16/08 (2013.01); C07K 16/10 (2013.01); C07K 16/1009 (2013.01); C07K 16/1027 (2013.01); C07K 16/1203 (2013.01); C07K 16/1232 (2013.01); C07K 16/1242 (2013.01); C07K 16/1271 (2013.01); C07K 16/1275 (2013.01); C07K 16/1282 (2013.01); C07K 16/1285 (2013.01); C07K 16/1289 (2013.01); G01N 33/6854 (2013.01); A61K 2039/507 (2013.01); C07K 2317/10 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); Y02A 50/30 (2018.01)] | 20 Claims |
1. A method of providing immunotherapy to a subject comprising administering to the subject an immunotherapeutic composition comprising:
A) immune globulin prepared from a pooled plasma composition comprising plasma samples from 500 or more human plasma donors, wherein the pooled plasma composition has a final respiratory syncytial virus (RSV) neutralization titer of at least 1800, and an antibody titer for parainfluenza virus 1, parainfluenza virus 2, influenza A virus, and/or influenza B virus that is at least 1.3 times greater than the antibody titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 500 or more random human plasma donors, and wherein less than 50% of the donor plasma samples used for pooling are from donors with a RSV neutralization titer of at least 1800; and
B) a pharmaceutically acceptable carrier;
wherein the immunotherapeutic composition is intravenously administered in a single dose to provide between 250-2500 milligram (mg) immune globulin per kilogram (kg) to the subject.
|